Cambridge-based CN Bio, an organ-on-a-chip company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Deepak Singh as vice-president of sales and marketing.

Singh has more than 30 years’ commercial experience within life sciences, providing leadership for sales and marketing teams to establish new technologies, from commercialisation through to global scale-up, as well as supporting expansion of existing products and services into the drug discovery, bioproduction, research and diagnostics markets.

He joins from PerkinElmer’s Horizon Discovery where he was head of global commercial. Before that, Deepak was vice-president of EMEA operations at Pacific Biosciences. He also held senior-level sales and marketing positions at Affymetrix and the genetic analysis unit of Applied Biosystems (formerly a PerkinElmer company).

Singh said: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised. As evidenced by the recent FDA Modernization Act 2.0 legislation in the US, this is a very promising time for the technology, and I am looking forward to joining the CN Bio team to bring their cutting-edge systems to more researchers across the globe, to enable decision-making within drug discovery workflows to be made with more confidence and earlier than ever before.”

Dr Paul Brooks, chief executive at CN Bio, commented: “Deepak’s business and leadership experience, alongside his life science background, is of huge value to CN Bio as we drive forward with the company’s commercial excellence strategy and build our capabilities in 2023 and beyond. Following the successful launch of our PhysioMimix Single-organ HT System in February, Deepak joins us at an exciting time and will be pivotal for the international scale-up of the marketing and distribution of this new system and our existing portfolio of MPS products and services.”